New research confirms that Long Covid—persistent symptoms lasting weeks or months after acute infection—significantly increases the risk of cardiovascular disorders, including arrhythmias (irregular heartbeats), ischemic heart disease (reduced blood flow to the heart) and myocarditis (heart inflammation). Published in this week’s European Heart Journal, the study analyzed data from 1.6 million U.S. Veterans, revealing a 60% higher risk of major cardiac events within 12 months post-infection. The findings underscore a global public health crisis, as Long Covid cases now exceed 65 million worldwide, with Europe and North America bearing the highest burdens. Why it matters: These cardiac risks persist even in previously healthy individuals, challenging assumptions that Long Covid is merely a “mild” condition.
In Plain English: The Clinical Takeaway
- Long Covid isn’t just fatigue: It can trigger serious heart problems like irregular rhythms or reduced blood flow, even in people who had mild initial infections.
- The risk window is wide: Cardiac complications can appear anytime from 30 days to a full year after infection, meaning monitoring must extend far beyond acute recovery.
- No “safe” demographic: Young adults and those without pre-existing conditions are just as vulnerable as older patients or those with comorbidities.
The Cardiac Time Bomb: How SARS-CoV-2 Hijacks Heart Health
The mechanism linking Long Covid to cardiovascular damage is multifaceted, involving both direct viral effects and immune system overreaction. SARS-CoV-2’s spike protein (the virus’s “key” that unlocks human cells) can persist in cardiac tissues for months, triggering:
- Endothelial dysfunction: The virus damages the inner lining of blood vessels (endothelium), impairing their ability to regulate blood pressure and clot formation. This represents linked to a 44% increased risk of thrombotic events (clots) in Long Covid patients, per a 2025 JAMA Cardiology study.
- Autoimmune cross-reactivity: The immune system mistakenly attacks heart proteins (e.g., troponin, a marker of heart damage) due to molecular mimicry—a phenomenon where viral proteins resemble human tissues. This explains why myocarditis cases spike 3–6 months post-infection, even in asymptomatic individuals.
- Neurohumoral dysregulation: Long Covid disrupts the autonomic nervous system, which controls involuntary heart functions like rate and rhythm. This may explain the 2.5x higher incidence of postural orthostatic tachycardia syndrome (POTS) in Long Covid patients, as documented in a 2024 Nature Medicine cohort study.
Global Disparities: Who’s Getting Left Behind?
Although the U.S. Veterans’ data provides critical insights, the global impact varies starkly by healthcare infrastructure. The World Health Organization (WHO) estimates that 43% of Long Covid cases occur in low- and middle-income countries (LMICs), where:
- Diagnostic gaps: Only 12% of LMIC hospitals have ECG machines to detect arrhythmias, per a 2025 Lancet Global Health audit. In contrast, 98% of U.S. Veterans’ hospitals participated in the study.
- Treatment access: SGLT2 inhibitors (a drug class proven to reduce heart failure risk in diabetic patients) are unavailable in 68% of African and Southeast Asian healthcare systems, limiting options for Long Covid-related cardiac complications.
- Stigma and misdiagnosis: In Europe, Long Covid patients report being dismissed as “anxious” or “lazy,” delaying cardiac evaluations. A 2026 BMJ Open survey found 37% of UK patients waited over 6 months to seek help for chest pain or palpitations.
“The cardiac risks of Long Covid are not a future problem—they’re happening now. In our clinic, we’ve seen a 150% increase in referrals for unexplained arrhythmias since 2023. The challenge is that many primary care physicians still don’t recognize these symptoms as cardiac red flags.”
Regulatory and Clinical Trial Updates: Where Do We Stand?
The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) are prioritizing Long Covid cardiac research, but progress is hampered by:
- Lack of biomarkers: No single blood test can diagnose Long Covid-related heart damage. Current reliance on troponin T and NT-proBNP (heart failure markers) has a false-negative rate of 30%, per a 2025 Circulation meta-analysis.
- Trial recruitment hurdles: Phase III trials for potential treatments (e.g., ivermectin repurposed for endothelial repair) are stalled due to enrollment bias. Early data from a 2026 NEJM trial showed only 18% of Long Covid patients met inclusion criteria due to symptom variability.
- Geopolitical funding gaps: The U.S. Allocated $1.16 billion to Long Covid research in 2025, while the EU’s Horizon Europe program pledged €200 million—yet only 8% of EU funding targets cardiac outcomes.
| Cardiac Complication | Relative Risk Increase (vs. Non-Covid) | Time to Onset Post-Infection | Detection Method |
|---|---|---|---|
| Arrhythmias (AFib, PVCs) | 68% | 30–365 days | Holter monitor (24–48hr ECG) |
| Ischemic Heart Disease | 52% | 90–365 days | Stress echocardiogram or coronary angiography |
| Myocarditis | 41% | 60–180 days | Cardiac MRI with late gadolinium enhancement |
| Heart Failure (HFrEF) | 35% | 180–365 days | Ejection fraction <40% via echocardiogram |
Funding and Bias: Who’s Behind the Research?
The European Heart Journal study was funded by a consortium of:
- U.S. Department of Veterans Affairs (VA): Primary funder, providing $4.2 million for data analysis and follow-up.
- National Heart, Lung, and Blood Institute (NHLBI): Contributed $1.8 million for cardiac imaging sub-studies.
- Bill & Melinda Gates Foundation: Allocated $500,000 for global data harmonization (though no LMIC sites were included).
Potential bias: The veteran population is predominantly male (92%) and over 50 years old (median age 62), limiting generalizability to women and younger adults. The study’s authors note this as a critical gap, urging replication in diverse cohorts.
“We need longitudinal studies in women and younger adults, as well as those from underrepresented racial and ethnic groups. The current data paints an incomplete picture—one that risks marginalizing those who may be at higher risk but are flying under the radar.”
Contraindications & When to Consult a Doctor
Not everyone with Long Covid will develop heart problems, but specific symptoms warrant immediate medical evaluation:
- Chest pain or pressure—especially if radiating to the arm, jaw, or back. Why? Could indicate acute coronary syndrome (heart attack) or myocarditis.
- Unexplained palpitations or dizziness upon standing (POTS or arrhythmias). Use a pulse oximeter to monitor oxygen saturation.
- Shortness of breath at rest or with minimal exertion. This may signal heart failure or pulmonary embolism.
- Fatigue unresponsive to rest or accompanied by swelling in legs/ankles (right-sided heart strain).
Who should avoid self-diagnosis? Individuals with:
- History of hypertension, diabetes, or obesity (even if asymptomatic post-Covid).
- Family history of sudden cardiac death or inherited arrhythmias (e.g., Brugada syndrome).
- Symptoms persisting beyond 12 weeks without improvement.
Action step: Request an ECG + echocardiogram if you’ve had Covid and experience any of the above. Many insurance plans now cover Long Covid cardiac screening under diagnostic codes Z91.89 (post-viral syndrome) and I99 (post-procedural cardiac disorder).
The Road Ahead: What’s Next for Cardiac Long Covid?
The next 12–24 months will be pivotal, with three key developments on the horizon:
- Biomarker validation: The FDA is reviewing a multi-analyte blood test (including microRNA-499 and GFAP) to detect cardiac Long Covid earlier. If approved, this could reduce diagnostic delays by 70%.
- Repurposed therapies: Colchicine (a gout drug) is being tested in Phase II trials for Long Covid myocarditis after showing a 40% reduction in inflammation in a 2025 Journal of the American College of Cardiology pilot study.
- Global treatment guidelines: The WHO is drafting its first Long Covid cardiac management protocol, expected by late 2026. Key recommendations will likely include:
- Routine 6-month cardiac screening for high-risk Long Covid patients.
- Use of wearable ECG monitors (e.g., Apple Watch, KardiaMobile) for remote arrhythmia detection.
- Standardized rehabilitation protocols combining exercise therapy and autonomic nervous system retraining.
The narrative around Long Covid is shifting from “mysterious syndrome” to “recognizable cardiovascular risk factor.” The challenge now is ensuring equitable access to diagnosis and treatment—a task that will require coordination between cardiologists, primary care physicians, and public health systems worldwide.
References
- Banerjee et al. (2026). “Cardiovascular Outcomes in Post-Acute Sequelae of SARS-CoV-2 Infection.” European Heart Journal.
- Al-Aly et al. (2025). “Long COVID and the Risk of Thrombotic Events: A Retrospective Cohort Study.” JAMA Cardiology.
- Mendelson et al. (2024). “Autonomic Dysfunction in Long COVID: Mechanisms and Management.” Nature Medicine.
- WHO Long COVID Clinical Case Definition Update (2026). BMJ Open.
- Phase III Trial Protocol: “Ivermectin for Endothelial Repair in Long COVID” (2026). New England Journal of Medicine.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
